The FDA's Priority List For 2016

Law360, New York (January 29, 2016, 11:03 AM ET) -- Erica Cribbs



Gretchen E. Harper



April E. Schweitzer The Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) director, Janet Woodcock, outlined the agency’s priorities for the coming year at the FDA/Centers for Medicare and Medicaid Summit for Biopharma Executives on Dec. 14-15, 2015.[1] The CDER, a subagency within the larger purview of the FDA, regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs, thereby ensuring that safe and effective drugs are available to improve the health of the U.S. population....

To view the full article, register now.